Research shows that Scheduled Tribes (ST) face high levels of chronic undernutrition, anaemia and iodine deficiency, as well as malaria. Geographical and socio-economic constraints mean that the toll of infectious diseases like tuberculosis, hepatitis, and HIV/AIDS can be uniquely high among these populations in some parts of the country, accompanied by a concomitant doubling in the prevalence of overweight/obesity across genders in ST populations. In addition to this, one in four tribal people has hypertension (figures are significantly higher in Gujarat and Kerala), and both the consumption of tobacco (10-18 points higher) and alcohol (14-21 points higher) greater as compared to non-tribal people. While great gains have been made in both understanding and eradicating disease burdens for these populations, health systems studies, and studies assessing service utilization and delivery are limited. Further, Community Health Workers or ASHAs, have helped in improving maternal and child health outcomes as wel

Background:Patients with advanced chronic kidney disease (CKD), including end-stage kidney disease (ESKD) patients receiving dialysis, are at increased risk of cardiovascular mortality, thrombotic cardiovascular events, and major bleeding complications. No trial has investigated effectiveness of antithrombotic agents in the prevention of cardiovascular events or death specifically in people with advanced stages of CKD or ESKD.Aim:To determine whether low dose rivaroxaban (2.5 mg twice daily), compared to placebo, significantly reduces the risk of a composite outcome of;Cardiovascular death,Non-fatal myocardial infarction,Stroke, orPeripheral arterial disease events,in patients with CKD stages 4 or 5 or dialysis-dependent ESKD, and an elevated cardiovascular risk (marked by the presence of coronary artery disease or peripheral arterial disease, or non-haemorrhagic non-lacunar stroke OR diabetes mellitus OR age ≥65 years).Research Methodology:The TRACK trial is an investigator-initiated, multicentre, internat

The Botnar Child Road Safety Challenge (BCRSC), funded by Fondation Botnar and managed by the Global Road Safety Partnership, is a programme that aims to reduce road traffic deaths and injuries. The BCRSC is designed to address locally relevant road safety problems that affect children in small- and mid-sized cities in seven priority countries (India, Mexico, Romania, South Africa, Tunisia, Tanzania and Vietnam) with practical, innovative and evidence-based interventions. The George Institute for Global Health is conducting monitoring for the BCRSC in order to assess the impact of interventions undertaken in terms of lives saved and crashes averted, process indicators (behaviour, knowledge, attitude), as well as outputs. As part of this work, The George Institute developed a set of four guidance notes under a Botnar Child Road Safety Challenge Toolkit to assist grantees. They are published here as they may be useful to other project teams working in similar contexts and employing Knowledge Action and